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Abstract
Background: Sirtuins (SIRT1-7) are a family of NAD-dependent deacetylases and/or ADP-ribosyltransferases that are
involved in metabolism, stress responses and longevity. SIRT3 is localized to mitochondria, where it deacetylates and
activates a number of enzymes involved in fuel oxidation and energy production.
Methodology/Principal Findings: In this study, we performed a proteomic screen to identify SIRT3 interacting proteins and
identified several subunits of complex II and V of the electron transport chain. Two subunits of complex II (also known as
succinate dehydrogenase, or SDH), SDHA and SDHB, interacted specifically with SIRT3. Using mass spectrometry, we
identified 13 acetylation sites on SDHA, including six novel acetylated residues. SDHA is hyperacetylated in SIRT3 KO mice
and SIRT3 directly deacetylates SDHA in a NAD-dependent manner. Finally, we found that SIRT3 regulates SDH activity both
in cells and in murine brown adipose tissue.
Conclusions/Significance: Our study identifies SDHA as a binding partner and substrate for SIRT3 deacetylase activity. SIRT3
loss results in decreased SDH enzyme activity, suggesting that SIRT3 may be an important physiological regulator of SDH
activity.
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Introduction
Protein lysine acetylation has emerged as a widespread post-
translational modification. Proteomic surveys of mammalian cells
have identified acetylation on nearly 2200 proteins distributed
throughout the cell, undermining the previous perception that
acetylation is a largely nuclear event [1]. However, our under-
standing of the factors that control acetylation and the conse-
quences of this modification remain incomplete.
Sirtuins are a family of class III histone deacetylases and/or
protein ADP-ribosyltransferases that are emerging as major
regulators of non-histone protein acetylation [2]. Mammals
possess seven sirtuins (SIRT1-7) that are, like lysine acetylation,
distributed throughout the cell. Sirtuins are increasingly implicated
in metabolism, stress responses and longevity [2], suggesting that
regulation of lysine acetylation by sirtuins can drive important
cellular processes. Intriguingly, sirtuin catalytic activity absolutely
requires NAD, leading many to speculate that sirtuin deacetylase
activity may be tied to the metabolic state of the cell [2].
Moreover, a strikingly high percentage of enzymes involved in
intermediate metabolism and energy production are acetylated
[1]. Together, these findings suggest that sirtuins may act as
nutrient-sensitive modulators of cellular metabolism, and growing
evidence supports this hypothesis [2].
Three sirtuins (SIRT3-5) are localized to the mitochondrion
and influence mitochondrial energy production, substrate oxida-
tion and apoptosis [3]. Of the three mitochondrial sirtuins, only
SIRT3 null (KO) mice display robust hyperacetylation of mito-
chondrial proteins, indicating that SIRT3 may be a major
mitochondrial deacetylase [4]. In fact, SIRT3 has been shown
to directly deacetylate and activate numerous mitochondrial
proteins, including acetyl CoA synthetase 2 (AceCS2) [5,6],
glutamate dehydrogenase (GDH) [4,7], isocitrate dehydrogenase 2
(IDH2) [7,8], long-chain acyl CoA dehydrogenase (LCAD) [9],
superoxide dismutase 2 (SOD2) [10,11], ornithine transcarba-
moylase (OTC) [12] and 3-hydroxy-3-methylglutaryl CoA syn-
thase 2 (HMGCS2) [13], and many additional proteins are
reported to be hyperacetylated in SIRT3 KO cells (reviewed in
ref. [3]). To expand our understanding of how SIRT3 regulates
mitochondrial metabolism, we utilized an unbiased proteomic
approach to identify SIRT3-interacting proteins. We found that
SIRT3 interacts with several subunits of complex II and V of the
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23295electron transport chain (ETC), and we established succinate
dehydrogenase (SDH), a member of both the ETC and
tricarboxylic acid (TCA) cycle, as a bona fide SIRT3 substrate.
Results
SIRT3 physically interacts with subunits of complex II and
complex V
SIRT3 is emerging as major regulator of many acetylated
mitochondrial proteins. To uncover potential SIRT3 targets, we
performed two independent experiments in which we identified
SIRT3-interacting proteins using mass spectrometry (MS) on
eluates of FLAG-IPs from HEK293T cells expressing empty
vector or SIRT3-FLAG. Candidate interacting proteins were
filtered using three criteria: 1) candidate must be identified in both
SIRT3 IPs; 2) candidate must not have any peptides identified in
control IPs, and 3) candidate must be localized to mitochondria
according to the MitoCarta compendium of mitochondrial pro-
teins [14]. Five proteins met these criteria: SIRT3, SDHA,
ATP5O/OSCP, HSDL2 and SLC16A1. The two major mito-
chondrial SIRT3-interacting proteins, SDHA and OSCP, are
subunits of oxidative phosphorylation complexes II and V,
respectively. We identified additional subunits of complex II
(SDHB) and complex V (ATP5A1 and ATP5F1) in SIRT3 IPs,
suggesting that SIRT3 may interact with the intact complexes.
Furthermore, we identified GDH and subunits of complex I
(NDUFA11 and NDUFS8), which were previously identified as
SIRT3 targets [4,7,15]. Next, we confirmed by immunoblotting
that, of the seven sirtuins, only SIRT3 physically interacts with
SDHA and OSCP (Fig. 1A). Using two separate antibody cocktail
kits, we found that SIRT3 specifically interacts with both the
SDHA and SDHB subunits of complex II (Fig. 1B, top and middle
panels). We also detected a non-specific interaction between
SIRT3 and the F1a subunit of complex V (ATP5A1) (Fig. 1B).
Many lysines on the surface of SDHA are acetylated
Our IP data indicated that among the seven sirtuins, SIRT3
specifically interacts with both the SDHA and SDHB subunits of
complex II. Several independent studies have found that SDHA,
but not SDHB, is acetylated [16–20]. In order to determine
whether SDHA or SDHB could be a target of SIRT3 deacetylase
activity, we immunopurified complex II from mouse liver
mitochondria and analyzed acetylation by mass spectrometry.
We identified a total of 13 acetylated lysines on SDHA and no
acetylation on SDHB. Of the 13 sites, 7 were previously identified
in mammalian proteomic surveys [16,18–20] (Table S1). We
additionally identified K182, K250, K480, K550, K624 and K633
as acetylated residues. SDHA is a highly conserved protein [21],
and many of these residues are conserved across metazoans (Table
S1). SDHA contains four domains: a FAD-binding domain, a
capping domain that closes the active site to solvent, a helical
domain and a C-terminal domain [22,23]. Acetylated lysines were
distributed throughout the amino-acid sequence in all four
domains of SDHA, with an increase in acetylation toward the
C-terminal end of the protein (Fig. 2A), and were found exclusively
on the outer surface of the protein (Fig. 2B). The fact that every
acetylation site is solute-accessible coupled with the lack of
acetylation at the interface between SDHA and SDHB suggests
that SDHA may be modified by acetylation after complex II
assembly.
Acetylation of SDHA is known to be influenced by fasting,
calorie restriction (CR) and SIRT3 expression [17–19]. In order to
better understand the genetic and physiological regulation of
SDHA acetylation, we immunopurified SDHA from liver
mitochondria of SIRT3 WT and KO mice, both fed and fasted,
in addition to control and CR mice and identified acetylated
lysines by MS. To our surprise, we did not detect a simple binary
diet or genotype-dependent regulation of modification (Table S1).
Interestingly, we did observe that CR increased acetylation levels at
seven lysines (Fig. S1), consistent with previous reports [18].
SIRT3 directly deacetylates SDHA
Having established SDHA as a highly acetylated SIRT3
interacting protein, we next sought to determine whether SIRT3
could regulate the level of SDHA acetylation. A previous study
found evidence of increased SDHA acetylation in SIRT3 KO
mice [17], but did not analyze acetylation of purified SDHA or the
ability of SIRT3 to deacetylate SDHA. To determine whether
complex II might be a direct substrate of SIRT3, we first assessed
the acetylation status of SDHA in SIRT3 WT and KO mouse
liver mitochondria. We found that immunopurified SDHA was
hyperacetylated in SIRT3 KO mitochondria (Fig. 3A). (Additional
exposures of the complex II IP and inputs from SIRT3 WT and
KO liver mitochondria are available in Appendix S1.) Similarly,
more SDHA was pulled down by immunoprecipitation of
acetylated proteins from SIRT3 KO mitochondria than from
Figure 1. SIRT3 interacts with subunits of complex II and complex V. FLAG-IPs were performed on HEK293T cells transiently expressing
FLAG-tagged sirtuins (T1-7). (A) SIRT1-7 IPs were immunoblotted with antibodies against SDHA, OSCP and FLAG. (B) SIRT3-5 IPs were immunoblotted
with an antibody cocktail recognizing the SDHA and SDHB subunits of complex II and the F1a subunit of complex V (top) or a cocktail containing
antibodies against representative subunits of complexes I–V (middle). SDHB is the subunit recognized by the complex II antibody.
doi:10.1371/journal.pone.0023295.g001
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similar results with GDH, a verified SIRT3 substrate [4,7]. Using
this method, we did not detect acetylation of SDHB (Fig. 3B). Next,
we assessed the ability of SIRT3 to directly deacetylate SDHA. We
incubated complex II purified from mouse liver mitochondria
with recombinant SIRT3 in the presence or absence of NAD
and nicotinamide (NAM), a sirtuin inhibitor. SIRT3, but not a
catalytically inactive mutant (SIRT3-H248Y), deacetylated SDHA
in a NAD-dependent manner (Fig. 3C). Together, these results
demonstrate that SDHA is a target of SIRT3 deacetylase activity.
Figure 2. SDHA is acetylated at 13 lysine residues. (A) Schematic of SDHA summarizing the four domains (FAD-binding, capping, helical and C-
terminal) with 13 identified acetylated residues shown in red (novel) or white (previously identified). (B) The 13 acetylated lysines were mapped on to
the corresponding residues of the crystal structure of avian complex II.
doi:10.1371/journal.pone.0023295.g002
Figure 3. SIRT3 deacetylates SDHA. Complex II (A) and acetylated proteins (B) were immunoprecipitated from liver mitochondria isolated from
SIRT3 WT and KO mice. IPs were immunoblotted with antibodies against acetyl-lysine (AcK), SDHA, SDHB and GDH. (C) Complex II
immunoprecipitated from mouse liver mitochondria was incubated with recombinant SIRT3 or catalytically inactive SIRT3 (SIRT3 H248Y) in the
presence or absence of NAD and NAM, a sirtuin inhibitor. After deacetylation, IPs were immunoblotted using antibodies against acetylated proteins,
SDHA and SIRT3. In all panels, antibodies against GFP were used as negative controls.
doi:10.1371/journal.pone.0023295.g003
SDHA Is a Target of SIRT3 Deacetylase Activity
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Complex II has a unique dual role in mitochondrial metabo-
lism: it is both a complex in ETC and an enzyme in the TCA
cycle. SDHA catalyzes the oxidation of succinate to fumarate and
electrons generated by this reaction are transferred through iron-
sulfur clusters in SDHB and on to the inner-membrane subunits,
SDHC and SDHD, where they are delivered to the quinone pool
of the ETC. Consequently, the complex has two distinct enzymatic
activities: succinate oxidation (SDH activity) and electron transfer
(complex II activity). A previous study detected diminished
complex II activity in SIRT3 KO liver mitochondria [17], but
the effect of SIRT3 on SDH activity has not been shown. Because
SDHA is the only known acetylated subunit of complex II, we
focused specifically on SDH activity. We found that SIRT3 KO
MEFs had a 25% reduction in SDH activity (Fig. 4A). Next, we
isolated mitochondria from SIRT3 WT and KO mice to
determine whether SIRT3 could influence SDH activity in vivo.
We observed no difference in SDH activity in liver mitochondria
(Fig. 4B), consistent with a previous report [15]. However, when
we measured SDH activity in brown adipose tissue (BAT), a highly
oxidative tissue in which several groups have reported functional
roles for SIRT3 [9,24–26], we found a 30% reduction in SDH
activity in SIRT3 KO mice (Fig. 4C). These results suggest that
acetylation of SDHA can affect SDH activity in vivo, perhaps in a
tissue- or context-specific manner.
Discussion
In this study, we identified subunits of complex II and complex
V as SIRT3 interacting proteins. The SDHA subunit of complex
II was previously shown to be hyperacetylated in SIRT3 KO mice.
We further examined SDHA, demonstrating that SIRT3 can
directly deacetylate SDHA and that succinate dehydrogenase
activity is reduced in SIRT3 KO cells and BAT from SIRT3 KO
mice. We found that the entire peripheral surface of SDHA can be
acetylated, implying that regulation of mitochondrial proteins by
acetylation may not always be as simple as modification at a single
residue triggering a change in activity. Moreover, despite our
specific analyses of SDHA acetylation, we did not detect acetyla-
tion at three previously-identified residues: K423, K517 and K538
[18,19]. It is possible that unidentified acetylated lysines still
remain to be discovered. Alternatively, acetylation could be
sequence-independent, designed to modify the surface of SDHA
rather than a particular residue. It will be interesting for future
studies to determine how acetylation influences SDH activity, the
regulation of SDH acetylation, and the specific residues or
domains that are involved.
Participating in both the TCA cycle and electron transport
chain, complex II is uniquely well situated to coordinate flux
through both pathways. Deacetylation of SDHA by SIRT3 could
therefore potently stimulate mitochondrial oxidative capacity in
response to nutrient stress. For example, CR induces SIRT3
expression [26] and dramatically reduces mitochondrial acetyla-
tion in BAT [18], a tissue in which SIRT3 regulates SDH activity.
CR-mediated induction of SIRT3 in BAT could facilitate SDHA
deacetylation and activation. Somewhat counter intuitively, how-
ever, we and others found that CR increases SDHA acetylation in
the liver [18]. As we did not see an effect of SIRT3 expression on
liver SDH activity, it is possible that acetylation of SDHA confers
alternative effects in liver, perhaps by regulating formation of
mitochondrial supercomplexes to facilitate electron transfer or
other complex II-protein interactions to influence substrate chan-
neling. It will be interesting for future studies to address how diet
and tissue-specific changes in acetylation influence SDHA
function.
Intriguingly, some acetylation sites are in close proximity to
residues that are mutated in human disease. For example, the
R554W mutation in humans reduces SDH activity and is
associated with Leigh’s syndrome [27]. R554 is near the substrate
entrance channel and mutation in this residue could affect
substrate entry or exit [21]. As K550 is on the same unstructured
loop, it is possible that K550 could also influence SDH activity in a
similar manner. Future studies may reveal new roles for
mitochondrial acetylation in human mitochondrial disorders.
The prevalence of acetylation on mitochondrial proteins—
particularly enzymes involved in metabolism—attests to the
importance of this post-translational modification. Indeed, dys-
regulation of the mitochondrial deacetylase SIRT3 is already
known to drive pathological states such as dilated cardiomyopathy
and tumorigenesis in mice [25,28–30]. Elucidation of the specific
consequences of mitochondrial protein acetylation, as well as
identification of the relevant acetyltransferases and deacetylases,
will be critical to our understanding of mitochondrial biology. It is
possible that in the future, directed modulation of mitochondrial
protein acetylation will hold therapeutic promise for these diseases.
Materials and Methods
Cell culture, plasmids and transfection
SIRT3 WT and KO mouse embryonic fibroblasts (MEFs) were
previously described [25]. HEK293T (ATCC) cells were cultured
in DMEM supplemented with 10% FBS, penicillin/streptomycin
and 2 mM L-glutamine; MEFs were cultured with an additional
0.1 mM beta-mercaptoethanol and non-essential amino acids.
Figure 4. SIRT3 regulates SDH activity. Succinate dehydrogenase activity was measured in (A) SIRT3 WT and KO MEF extracts (n=4), (B) liver
mitochondria (n=3) and (C) brown adipose tissue (BAT) mitochondria (n=6–7). SDH activity was normalized to sample protein content and
expressed as a ratio of WT levels. Values are expressed as mean 6SEM. *, P,0.05.
doi:10.1371/journal.pone.0023295.g004
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transfection reagent (Roche). SIRT1-7 plasmids with C-terminal
FLAG-tags were previously described [31,32].
Animal studies
Animal studies were performed according to protocols approved
by the Institutional Animal Care and Use Committee, the Standing
Committee on Animals at Harvard. Male 129Sv SIRT3 WT and
KO [4] littermates (a generous gift from Dr. Fred Alt) were fed a
normal chow diet (PicoLab diet 5053). For calorie restriction (CR)
experiments, 12-week old male C57BL/6 mice (Jackson Laborato-
ries)were placedona stepwise 3month 40%CRregimen according
to a modified version of an established protocol [33].
Immunoprecipitation and immunoblotting
FLAG immunoprecipitations (IPs) were performed as described
[25]. For all other IPs, mitochondria were isolated from liver of
SIRT3 WT or KO mice according to established methods [34].
Acetylated proteins were purified using anti-acetyl-lysine antibody
bound to protein G agarose (Invitrogen), with 10 mM nicotin-
amide and 400 nM trichostatin A added to the IP buffer. A
complex II immunocapture kit (MitoSciences) was used to purify
complex II from isolated mitochondria according to manufacturer
instructions. Immunoprecipitations with anti-GFP antibodies were
used for negative controls. The following antibodies were used:
Total OXPHOS antibody cocktail, complex II antibody cocktail
and OSCP (Mitosciences); Flag (Sigma); SIRT3 and acetyl-lysine
(Cell Signaling); GFP (Santa Cruz), and GDH (USBiological).
Mass spectrometry
To determine proteins interacting with SIRT3, FLAG IPs were
performed as described above on cells expressing empty vector or
SIRT3-FLAG. After washing, IPs were eluted with FLAG peptides,
disulfide bonds were reduced with 5 mM DTT and cysteine
residues alkylated with 15 mM iodoacteamide. Proteins were
precipitated by adding trifluoro acetic acid (TCA, 25%, w/w), then
resuspended in 1 M urea and 50 mM Tris (pH 8.5) and digested by
incubation with 1.6 mg trypsin (seuquencing grade, Promega) at
37uCfor12 hours.Peptideswere desaltedusingC18StageTips[35].
To map the acetylation sites on SDHA, complex II was
immunoprecipitated as described above, run on an SDS-PAGE
gel and stained with Coomassie blue. The 70 kDa band cor-
responding to SDHA was excised and treated with DTT and
iodoacetamide. The protein was then digested in-gel using trypsin,
and peptides were desalted as described above. Both samples were
analyzed using nano-scale microcapillary C18 liquid chromatogra-
phy (LC-MS/MS) on either an LTQ Orbitrap XL or an LTQ
Orbitrap Velos mass spectrometer (Thermo Scientific) equipped
with an Agilent 1100 binary HPLC pump (Agilent, Santa Clara,
CA) essentially as described previously [36]. MS/MS spectra were
assigned using the SEQUEST algorithm by searching them against
a target-decoy protein sequence database based on the mouse IPI
database (v 3.60) to which protein sequences of SIRT3-FLAG and
of common contaminants were added. Enzyme specificity was set to
tryptic, cysteine residues were searched as carbamidomethylated,
methionine residues were allowed to be oxidized, lysine residues
were allowed to be acetylated for the acetylation site mapping and
up to 2 or 4 (acetylation site mapping) missed cleavages on tryptic
cleavage sites were accepted. All peptide assignments were filtered
to a false-discovery rate (FDR) of smaller than 1% by applying the
target-decoy database search strategy [37] using a linear discrim-
ination analysis method as described previously [38]. The resulting
MS/MS data set was filtered further to obtain an protein
identification FDR of smaller than 1% [38]. MS/MS spectra of
acetylated SDHA peptides were manually validated.
Deacetylation reactions
Recombinant SIRT3 was purchased from Biomol. His-tagged
SIRT3 and SIRT3-H248Y were purified from E. coli as described
[5]. Complex II was immunoprecipitated from SIRT3 KO liver
mitochondria and incubated for 2 hours at 37uC in SDAC buffer
(50 mM Tris?HCl (pH 9.0), 4 mM MgCl2, 50 mM NaCl, 0.5 mM
DTT) in the presence or absence of recombinant enzyme, 1 mM
NAD or 10 mM nicotinamide.
SDH activity assays
SDH activity was measured from purified liver or brown adipose
tissue mitochondria resuspended to a final concentration of 1 mg/
ml in buffer B (280 mM sucrose, 10 mM Tris, pH 7.4). 30 mg mito-
chondria were used to assay dichlorophenolindophenol (DCPIP)
reductionin 1.0 mL of 50 mM50 mMKH2PO4 (pH 7.5), 1.5 mM
KCN, 1 mM PMS and 17.5 mM succinate. Malonate-sensitive
SDH activity was measured in MEFs that were quickly freeze-
thawed in liquid nitrogen and resuspended in buffer A (250 mM
sucrose, 20 mM Tris, 2 mM EDTA, 1 mg/ml BSA, pH 7.2).
DCPIPreductionwasmeasuredon5610
5cellsasformitochondria,
with the addition of 0.2 mM thenoyltrifluoroacetone to the reaction
mixture. Samples were measured in duplicate against a reference
cuvette containing 10 mM sodium malonate. The rate of DCPIP
reduction was measured by the decrease in absorption at 600 nm.
Structural modelling
Residues corresponding to the mouse acetylated lysines were
mapped onto avian complex II (PDB 2H89) [39]. Molecular
graphics images were produced using the UCSF Chimera package
from the Resource for Biocomputing, Visualization, and Infor-
matics at the University of California, San Francisco (supported by
NIH P41 RR001081) [40].
Supporting Information
Figure S1 CR increases SDHA acetylation. The relative
abundance of acetylation at specific lysine residues was assessed by
semiquantitative mass spectrometry.
(TIF)
Table S1 SDHA immunopurified from liver mitochondria of
control(C),calorie restricted (CR), SIRT3 wild-type (WT) orknock-
out (KO) mice that were fed or fasted for 48 h was analyzed for
acetylation by mass spectrometry. The 13 identified sites are
indicated by ‘x’. The 6 novel sites are shown in red. Sites previously
identified by proteomic studies of mouse liver mitochondria are
shown in white, with appropriate citation. Sequences of SDHA
were aligned using the Clustal W algorithm and are shown in green
(conserved lysine) or yellow (not conserved).
(XLS)
Appendix S1 SDHA is hyperacetylated in SIRT3 KO
mice. (A) Additional exposures of Western blot of complex II IP
described in Fig. 3A. (B) Western blot of the input from the
complex II IP illustrating hyperacetylation of several mitochon-
drial proteins in SIRT3 KO liver. AcK, acetyl-lysine.
(TIF)
Acknowledgments
We thank Eric Verdin for the gift of the sirtuin plasmids and John Dominy
and Brian North for help with deacetylation assays.
SDHA Is a Target of SIRT3 Deacetylase Activity
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23295Author Contributions
Conceived and designed the experiments: LWSF WH DCW VP SPG
MCH. Performed the experiments: LWSF WH VD-D. Analyzed the data:
LWSF WH VD-D. Wrote the paper: LWSF MCH.
References
1. Guan KL, Xiong Y (2011) Regulation of intermediary metabolism by protein
acetylation. Trends Biochem Sci 36: 108–116.
2. Finkel T, Deng CX, Mostoslavsky R (2009) Recent progress in the biology and
physiology of sirtuins. Nature 460: 587–591.
3. Verdin E, Hirschey MD, Finley LW, Haigis MC (2010) Sirtuin regulation of
mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci
35: 669–675.
4. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, et al. (2007)
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine
acetylation. Mol Cell Biol 27: 8807–8814.
5. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E (2006) Reversible
lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA
synthetase 2. Proc Natl Acad Sci U S A 103: 10224–10229.
6. Hallows WC, Lee S, Denu JM (2006) Sirtuins deacetylate and activate
mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A 103:
10230–10235.
7. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, et al. (2008)
Substrates and regulation mechanisms for the human mitochondrial sirtuins
Sirt3 and Sirt5. J Mol Biol 382: 790–801.
8. Someya S, Yu W, Hallows WC, Xu J, Vann JM, et al. (2010) Sirt3 mediates
reduction of oxidative damage and prevention of age-related hearing loss under
caloric restriction. Cell 143: 802–812.
9. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, et al. (2010) SIRT3
regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.
Nature 464: 121–125.
10. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, et al. (2010) Sirt3-
mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD
activity in response to stress. Mol Cell 40: 893–904.
11. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D (2010) Calorie restriction
reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12:
662–667.
12. Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, et al. (2011) Sirt3
promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol
Cell 41: 139–149.
13. Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, et al. (2010)
SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2
and regulates ketone body production. Cell Metab 12: 654–661.
14. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, et al. (2008) A
mitochondrial protein compendium elucidates complex I disease biology. Cell
134: 112–123.
15. Ahn BH, Kim HS, Song S, Lee IH, Liu J, et al. (2008) A role for the
mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl
Acad Sci U S A 105: 14447–14452.
16. Zhao S, Xu W, Jiang W, Yu W, Lin Y, et al. (2010) Regulation of cellular
metabolism by protein lysine acetylation. Science 327: 1000–1004.
17. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, et al. (2010) Regulation of
succinate dehydrogenase activity by SIRT3 in mammalian mitochondria.
Biochemistry 49: 304–311.
18. Schwer B, Eckersdorff M, Li Y, Silva JC, Fermin D, et al. (2009) Calorie
restriction alters mitochondrial protein acetylation. Aging Cell 8: 604–606.
19. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, et al. (2006) Substrate and functional
diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23:
607–618.
20. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, et al. (2009) Lysine
acetylation targets protein complexes and co-regulates major cellular functions.
Science 325: 834–840.
21. Cecchini G (2003) Function and structure of complex II of the respiratory chain.
Annu Rev Biochem 72: 77–109.
22. Ackrell BA (2000) Progress in understanding structure-function relationships in
respiratory chain complex II. FEBS Lett 466: 1–5.
23. Sun F, Huo X, Zhai Y, Wang A, Xu J, et al. (2005) Crystal structure of
mitochondrial respiratory membrane protein complex II. Cell 121: 1043–1057.
24. Giralt A, Hondares E, Villena JA, Ribas F, Diaz-Delfin J, et al. (2011)
Peroxisome Proliferator-activated Receptor-{gamma} Coactivator-1{alpha}
Controls Transcription of the Sirt3 Gene, an Essential Component of the
Thermogenic Brown Adipocyte Phenotype. J Biol Chem 286: 16958–16966.
25. Finley LW, Carracedo A, Lee J, Souza A, Egia A, et al. (2011) SIRT3 opposes
reprogramming of cancer cell metabolism through HIF1alpha destabilization.
Cancer Cell 19: 416–428.
26. Shi T, Wang F, Stieren E, Tong Q (2005) SIRT3, a mitochondrial sirtuin
deacetylase, regulates mitochondrial function and thermogenesis in brown
adipocytes. J Biol Chem 280: 13560–13567.
27. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, et al. (1995)
Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial
respiratory chain deficiency. Nat Genet 11: 144–149.
28. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, et al. (2010)
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance
of mitochondrial integrity and metabolism during stress. Cancer Cell 17: 41–52.
29. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, et al. (2009) Sirt3
blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent
antioxidant defense mechanisms in mice. J Clin Invest 119: 2758–2771.
30. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, et al. (2010) Regulation
of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses
age-related cardiac hypertrophy. Aging (Albany NY) 2: 914–923.
31. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, et al.
(2006) SIRT4 inhibits glutamate dehydrogenase and opposes the effects of
calorie restriction in pancreatic beta cells. Cell 126: 941–954.
32. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003) The human Sir2
ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11:
437–444.
33. Pugh TD, Klopp RG, Weindruch R (1999) Controlling caloric consumption:
protocols for rodents and rhesus monkeys. Neurobiol Aging 20: 157–165.
34. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, et al. (2005)
Extension of murine life span by overexpression of catalase targeted to
mitochondria. Science 308: 1909–1911.
35. Rappsilber J, Ishihama Y, Mann M (2003) Stop and go extraction tips for
matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS
sample pretreatment in proteomics. Anal Chem 75: 663–670.
36. Haas W, Faherty BK, Gerber SA, Elias JE, Beausoleil SA, et al. (2006)
Optimization and use of peptide mass measurement accuracy in shotgun
proteomics. Mol Cell Proteomics 5: 1326–1337.
37. Elias JE, Gygi SP (2007) Target-decoy search strategy for increased confidence
in large-scale protein identifications by mass spectrometry. Nat Methods 4:
207–214.
38. Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, et al. (2010) A
tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143:
1174–1189.
39. Huang LS, Shen JT, Wang AC, Berry EA (2006) Crystallographic studies of the
binding of ligands to the dicarboxylate site of Complex II, and the identity of the
ligand in the ‘‘oxaloacetate-inhibited’’ state. Biochim Biophys Acta 1757:
1073–1083.
40. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al.
(2004) UCSF Chimera–a visualization system for exploratory research and
analysis. J Comput Chem 25: 1605–1612.
SDHA Is a Target of SIRT3 Deacetylase Activity
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23295